Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 62

Cited In for PubMed (Select 21642991)


BAP1 hereditary cancer predisposition syndrome: a case report and review of literature.

Klebe S, Driml J, Nasu M, Pastorino S, Zangiabadi A, Henderson D, Carbone M.

Biomark Res. 2015 Jul 2;3:14. doi: 10.1186/s40364-015-0040-5. eCollection 2015.


Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.

Sacco JJ, Kenyani J, Butt Z, Carter R, Chew HY, Cheeseman LP, Darling S, Denny M, Urbé S, Clague MJ, Coulson JM.

Oncotarget. 2015 May 30;6(15):13757-71.


Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.

Kalra N, Zhang J, Thomas A, Xi L, Cheung M, Talarchek J, Burkett S, Tsokos MG, Chen Y, Raffeld M, Miettinen M, Pastan I, Testa JR, Hassan R.

BMC Cancer. 2015 May 8;15:376. doi: 10.1186/s12885-015-1362-2.


BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.

Alakus H, Yost SE, Woo B, French R, Lin GY, Jepsen K, Frazer KA, Lowy AM, Harismendy O.

J Transl Med. 2015 Apr 16;13:122. doi: 10.1186/s12967-015-0485-1.


The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.

Liao L, Testa JR, Yang H.

Cancer Genet. 2015 May;208(5):206-14. doi: 10.1016/j.cancergen.2015.02.008. Epub 2015 Feb 20. Review.


BAP1 missense mutation c.2054 A>T (p.E685V) completely disrupts normal splicing through creation of a novel 5' splice site in a human mesothelioma cell line.

Morrison A, Chekaluk Y, Bacares R, Ladanyi M, Zhang L.

PLoS One. 2015 Apr 1;10(4):e0119224. doi: 10.1371/journal.pone.0119224. eCollection 2015.


NF2 blocks Snail-mediated p53 suppression in mesothelioma.

Cho JH, Lee SJ, Oh AY, Yoon MH, Woo TG, Park BJ.

Oncotarget. 2015 Apr 30;6(12):10073-85.


Hippo/YAP pathway for targeted therapy.

Felley-Bosco E, Stahel R.

Transl Lung Cancer Res. 2014 Apr;3(2):75-83. doi: 10.3978/j.issn.2218-6751.2014.02.03. Review.


Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing.

Sheffield BS, Tinker AV, Shen Y, Hwang H, Li-Chang HH, Pleasance E, Ch'ng C, Lum A, Lorette J, McConnell YJ, Sun S, Jones SJ, Gown AM, Huntsman DG, Schaeffer DF, Churg A, Yip S, Laskin J, Marra MA.

PLoS One. 2015 Mar 23;10(3):e0119689. doi: 10.1371/journal.pone.0119689. eCollection 2015.


Recent insights emerging from malignant mesothelioma genome sequencing.

Carbone M, Gaudino G, Yang H.

J Thorac Oncol. 2015 Mar;10(3):409-11. doi: 10.1097/JTO.0000000000000466. No abstract available.


High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.

Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Luk H, Baumann F, Zhang YA, Gazdar A, Kanodia S, Tiirikainen M, Flores E, Gaudino G, Becich MJ, Pass HI, Yang H, Carbone M.

J Thorac Oncol. 2015 Apr;10(4):565-76. doi: 10.1097/JTO.0000000000000471.


Concurrent occurrence of renal cell carcinoma with rhabdoid features in a married couple: a case report.

Matsumoto R, Shinohara N, C-Hatanaka K, Kuroda N, Tsuchiya K, Maruyama S, Abe T, Nonomura K.

BMC Res Notes. 2015 Jan 15;8:3. doi: 10.1186/s13104-014-0957-z.


BAP1 has a survival role in cutaneous melanoma.

Kumar R, Taylor M, Miao B, Ji Z, Njauw JC, Jönsson G, Frederick DT, Tsao H.

J Invest Dermatol. 2015 Apr;135(4):1089-97. doi: 10.1038/jid.2014.528. Epub 2014 Dec 18.


BRCA1-associated protein 1 (BAP1) deubiquitinase antagonizes the ubiquitin-mediated activation of FoxK2 target genes.

Okino Y, Machida Y, Frankland-Searby S, Machida YJ.

J Biol Chem. 2015 Jan 16;290(3):1580-91. doi: 10.1074/jbc.M114.609834. Epub 2014 Dec 1.


Overview of the biochemical and genetic processes in malignant mesothelioma.

Assis LV, Isoldi MC.

J Bras Pneumol. 2014 Jul-Aug;40(4):429-42. Review. English, Portuguese. Erratum in: J Bras Pneumol. 2014 Oct;40(5):588.


A meta-analysis of multiple matched copy number and transcriptomics data sets for inferring gene regulatory relationships.

Newton R, Wernisch L.

PLoS One. 2014 Aug 22;9(8):e105522. doi: 10.1371/journal.pone.0105522. eCollection 2014.


Current issues in malignant pleural mesothelioma evaluation and management.

Ai J, Stevenson JP.

Oncologist. 2014 Sep;19(9):975-84. doi: 10.1634/theoncologist.2014-0122. Epub 2014 Jul 24.


Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing.

Kalirai H, Dodson A, Faqir S, Damato BE, Coupland SE.

Br J Cancer. 2014 Sep 23;111(7):1373-80. doi: 10.1038/bjc.2014.417. Epub 2014 Jul 24.


Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.

Li W, Cooper J, Zhou L, Yang C, Erdjument-Bromage H, Zagzag D, Snuderl M, Ladanyi M, Hanemann CO, Zhou P, Karajannis MA, Giancotti FG.

Cancer Cell. 2014 Jul 14;26(1):48-60. doi: 10.1016/j.ccr.2014.05.001.


Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma.

Marek LA, Hinz TK, von Mässenhausen A, Olszewski KA, Kleczko EK, Boehm D, Weiser-Evans MC, Nemenoff RA, Hoffmann H, Warth A, Gozgit JM, Perner S, Heasley LE.

Mol Cancer Res. 2014 Oct;12(10):1460-9. doi: 10.1158/1541-7786.MCR-14-0038. Epub 2014 Jun 25.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk